journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/28430176/low-absolute-peripheral-blood-cd4-t-cell-count-predicts-poor-prognosis-in-r-chop-treated-patients-with-diffuse-large-b-cell-lymphoma
#1
Y Kusano, M Yokoyama, Y Terui, N Nishimura, Y Mishima, K Ueda, N Tsuyama, Y Hirofumi, A Takahashi, N Inoue, K Takeuchi, K Hatake
The absolute peripheral blood lymphocyte count at diagnosis is known to be a strong prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but it remains unclear as to which peripheral blood lymphocyte population is reflective of DLBCL prognosis. In this cohort, 355 patients with DLBCL treated with R-CHOP from 2006 to 2013 were analyzed. The low absolute CD4+ T-cell count (ACD4C) at diagnosis negatively correlated with the overall response rate and the complete response rate significantly (P<0...
April 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28430175/carfilzomib-lenalidomide-dexamethasone-vs-lenalidomide-dexamethasone-in-relapsed-multiple-myeloma-by-previous-treatment
#2
M A Dimopoulos, A K Stewart, T Masszi, I Špička, A Oriol, R Hájek, L Rosiñol, D Siegel, G G Mihaylov, V Goranova-Marinova, P Rajnics, A Suvorov, R Niesvizky, A Jakubowiak, J San-Miguel, H Ludwig, S Ro, S Aggarwal, P Moreau, A Palumbo
Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide-dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomide-dexamethasone (KRd) was based on results from the randomized, phase 3 study ASPIRE (NCT01080391), which showed KRd significantly improved progression-free survival (PFS) vs Rd (median 26.3 vs 17.6 months; hazard ratio (HR)=0.690; P=0.0001). This subgroup analysis of ASPIRE evaluated KRd vs Rd by number of previous lines of therapy and previous exposure to bortezomib, thalidomide or lenalidomide...
April 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28430174/whole-exome-analysis-reveals-novel-somatic-genomic-alterations-associated-with-cell-of-origin-in-diffuse-large-b-cell-lymphoma
#3
B A Manso, K Wenzl, Y W Asmann, M J Maurer, M Manske, Z-Z Yang, S L Slager, G S Nowakowski, S M Ansell, T E Witzig, A L Feldman, L Rimsza, B Link, J R Cerhan, A J Novak
No abstract text is available yet for this article.
April 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28430173/liver-function-test-abnormalities-and-their-clinical-relevance-in-primary-myelofibrosis
#4
D Barraco, M Mudireddy, S Shah, C A Hanson, R P Ketterling, N Gangat, A Pardanani, A Tefferi
No abstract text is available yet for this article.
April 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28430172/ezh2-alterations-in-follicular-lymphoma-biological-and-clinical-correlations
#5
S Huet, L Xerri, B Tesson, S Mareschal, S Taix, L Mescam-Mancini, E Sohier, M Carrère, J Lazarovici, O Casasnovas, L Tonon, S Boyault, S Hayette, C Haioun, B Fabiani, A Viari, F Jardin, G Salles
The histone methyltransferase EZH2 has an essential role in the development of follicular lymphoma (FL). Recurrent gain-of-function mutations in EZH2 have been described in 25% of FL patients and induce aberrant methylation of histone H3 lysine 27 (H3K27). We evaluated the role of EZH2 genomic gains in FL biology. Using RNA sequencing, Sanger sequencing and SNP-arrays, the mutation status, copy-number and gene-expression profiles of EZH2 were assessed in a cohort of 159 FL patients from the PRIMA trial. Immunohistochemical (IHC) EZH2 expression (n=55) and H3K27 methylation (n=63) profiles were also evaluated...
April 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28430171/the-prognostic-value-of-18-fdg-positron-emission-tomography-in-t-cell-non-hodgkin-lymphoma
#6
R Eslick, L Dunlop, M Lin, D Hsu, S Ling
No abstract text is available yet for this article.
April 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28409770/acute-myeloid-leukemia-targets-for-bispecific-antibodies
#7
S S Hoseini, N K Cheung
No abstract text is available yet for this article.
April 14, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28387753/imatinib-mesylate-inhibits-stat5-phosphorylation-in-response-to-il-7-and-promotes-t-cell-lymphopenia-in-chronic-myelogenous-leukemia-patients
#8
S Thiant, M M Moutuou, P Laflamme, R Sidi Boumedine, D M Leboeuf, L Busque, J Roy, M Guimond
Imatinib mesylate (IM) therapy has been shown to induce lower T cell counts in chronic myelogenous leukemia (CML) patients and an interference of IM with T cell receptor (TCR) signaling has been invoked to explain this observation. However, IL-7 and TCR signaling are both essential for lymphocyte survival. This study was undertaken to determine whether IM interferes with IL-7 or TCR signaling to explain lower T cell counts in patients. At diagnosis, CML patients have typically lower CD4(+) counts in their blood, yet CD8(+) counts are normal or even increased in some...
April 7, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28362442/prevalence-of-hepatitis-b-and-hepatitis-c-viral-infections-in-various-subtypes-of-b-cell-non-hodgkin-lymphoma-confirmation-of-the-association-with-splenic-marginal-zone-lymphoma
#9
W Xiong, R Lv, H Li, Z Li, H Wang, W Liu, D Zou, L Qiu, S Yi
No abstract text is available yet for this article.
March 31, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28362441/overexpression-of-ezh2-in-multiple-myeloma-is-associated-with-poor-prognosis-and-dysregulation-of-cell-cycle-control
#10
C Pawlyn, M D Bright, A F Buros, C K Stein, Z Walters, L I Aronson, F Mirabella, J R Jones, M F Kaiser, B A Walker, G H Jackson, P A Clarke, P L Bergsagel, P Workman, M Chesi, G J Morgan, F E Davies
Myeloma is heterogeneous at the molecular level with subgroups of patients characterised by features of epigenetic dysregulation. Outcomes for myeloma patients have improved over the past few decades except for molecularly defined high-risk patients who continue to do badly. Novel therapeutic approaches are, therefore, required. A growing number of epigenetic inhibitors are now available including EZH2 inhibitors that are in early-stage clinical trials for treatment of haematological and other cancers with EZH2 mutations or in which overexpression has been correlated with poor outcomes...
March 31, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28362440/prognostic-relevance-of-lymphocytopenia-monocytopenia-and-lymphocyte-to-monocyte-ratio-in-primary-myelodysplastic-syndromes-a-single-center-experience-in-889-patients
#11
L Saeed, M M Patnaik, K H Begna, A Al-Kali, M R Litzow, C A Hanson, R P Ketterling, L F Porrata, A Pardanani, N Gangat, A Tefferi
Current prognostic models for myelodysplastic syndromes (MDS), including the Revised International Prognostic Scoring System (IPSS-R), do not account for host immunity. We retrospectively examined the prognostic relevance of monocytopenia, lymphocytopenia and lymphocyte-to-monocyte ratio (LMR) in a cohort of 889 patients with primary MDS. After a median follow-up of 27 months, 712 (80%) deaths and 116 (13%) leukemic transformation were documented. In univariate analysis, subnormal absolute lymphocyte count (ALC) <0...
March 31, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28338672/posttransplant-maintenance-therapy-in-multiple-myeloma-the-changing-landscape
#12
REVIEW
S Sengsayadeth, F Malard, B N Savani, L Garderet, M Mohty
Transplant-eligible patients with multiple myeloma (MM) now have extended survival after diagnosis owing to effective modern treatment strategies that include new agents in induction therapy, autologous stem cell transplant (ASCT), consolidation therapy and posttransplant maintenance therapy. Standard of care for newly diagnosed, fit patients includes ASCT and, often nowadays, posttransplant maintenance. Several large studies have shown the efficacy of maintenance with thalidomide, lenalidomide and bortezomib in the treatment scheme of MM with regards to prolonging progression-free survival and, to a lesser degree, overall survival...
March 24, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28338671/regulatory-b-cell-myeloma-cell-interaction-confers-immunosuppression-and-promotes-their-survival-in-the-bone-marrow-milieu
#13
L Zhang, Y-T Tai, M Ho, L Xing, D Chauhan, A Gang, L Qiu, K C Anderson
No abstract text is available yet for this article.
March 24, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28338670/encouraging-impact-of-doxycycline-on-early-mortality-in-cardiac-light-chain-al-amyloidosis
#14
A D Wechalekar, C Whelan
No abstract text is available yet for this article.
March 24, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28304403/high-dose-chemotherapy-followed-by-autologous-transplantation-may-overcome-the-poor-prognosis-of-diffuse-large-b-cell-lymphoma-patients-with-myc-bcl2-co-expression
#15
F Maura, A Guidetti, A Pellegrinelli, A Dodero, M Pennisi, C Caprioli, A Testi, L Farina, N Bolli, L F Devizzi, A Cabras, P Corradini
No abstract text is available yet for this article.
March 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28304402/prospective-longitudinal-study-on-quality-of-life-in-relapsed-refractory-multiple-myeloma-patients-receiving-second-or-third-line-lenalidomide-or-bortezomib-treatment
#16
X Leleu, C Kyriakou, I Vande Broek, P Murphy, P Bacon, P Lewis, H Gilet, B Arnould, M T Petrucci
Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line lenalidomide or bortezomib treatment were measured in a prospective European multicentre, observational study at different time points. At baseline, patients in the lenalidomide cohort were frailer than in the bortezomib cohort with more rapid disease progression at study entry (more patients with Eastern Cooperative Oncology Group performance status >2, shorter time from diagnosis, more chronic heart failure, higher serum creatinine levels, more patients with dialysis required)...
March 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28282035/randomized-phase-3-study-of-elotuzumab-for-relapsed-or-refractory-multiple-myeloma-eloquent-2-japanese-patient-subanalysis
#17
K Suzuki, K Sunami, K Ohashi, S Iida, T Mori, H Handa, K Matsue, M Miyoshi, E Bleickardt, M Matsumoto, M Taniwaki
No abstract text is available yet for this article.
March 10, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28282034/prognostic-impact-of-bone-marrow-fibrosis-in-polycythemia-vera-validation-of-the-iwg-mrt-study-and-additional-observations
#18
D Barraco, S Cerquozzi, C A Hanson, R P Ketterling, A Pardanani, N Gangat, A Tefferi
In 2012, the International Working Group for Myeloproliferative Neoplasms (MPN) Research and Treatment (IWG-MRT) reported an associations between mild bone marrow (BM) fibrosis (⩾grade 1) in polycythemia vera (PV) and a lower incidence of thrombosis during the clinical course and a higher risk of fibrotic progression. The objective in the current study of 262 patients with PV was to validate these observations and also identify other risk factors for myelofibrosis-free survival (MFFS). About 127 (48%) patients displayed ⩾grade 1 reticulin fibrosis at the time of diagnosis; presenting clinical and laboratory features were not significantly different between patients with or without BM fibrosis...
March 10, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28282033/pi3k%C3%AE-and-pi3k%C3%AE-isoforms-have-distinct-functions-in-regulating-pro-tumoural-signalling-in-the-multiple-myeloma-microenvironment
#19
R E Piddock, N Loughran, C R Marlein, S D Robinson, D R Edwards, S Yu, G E Pillinger, Z Zhou, L Zaitseva, M J Auger, S A Rushworth, K M Bowles
Phosphoinositide-3-kinase and protein kinase B (PI3K-AKT) is upregulated in multiple myeloma (MM). Using a combination of short hairpin RNA (shRNA) lentivirus-mediated knockdown and pharmacologic isoform-specific inhibition we investigated the role of the PI3K p110γ (PI3Kγ) subunit in regulating MM proliferation and bone marrow microenvironment-induced MM interactions. We compared this with inhibition of the PI3K p110δ (PI3kδ) subunit and with combined PI3kδ/γ dual inhibition. We found that MM cell adhesion and migration were PI3Kγ-specific functions, with PI3kδ inhibition having no effect in MM adhesion or migration assays...
March 10, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28282032/germline-mutations-predisposing-to-diffuse-large-b-cell-lymphoma
#20
O C Leeksma, N F de Miranda, H Veelken
No abstract text is available yet for this article.
March 10, 2017: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"